CO5570656A2 - Liberacin controlada de una sustancia activa a un entorno rico en grasa - Google Patents

Liberacin controlada de una sustancia activa a un entorno rico en grasa

Info

Publication number
CO5570656A2
CO5570656A2 CO05056576A CO05056576A CO5570656A2 CO 5570656 A2 CO5570656 A2 CO 5570656A2 CO 05056576 A CO05056576 A CO 05056576A CO 05056576 A CO05056576 A CO 05056576A CO 5570656 A2 CO5570656 A2 CO 5570656A2
Authority
CO
Colombia
Prior art keywords
composition
active substance
environment
controlled release
weight
Prior art date
Application number
CO05056576A
Other languages
English (en)
Inventor
Mark Brian Chidlaw
Thomas Friesen Dwayne
Scott Max Herbig
Nightingale James Alan Schriver
West James Blair
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of CO5570656A2 publication Critical patent/CO5570656A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

1.- Un procedimiento para la liberación controlada de una sustancia activa a un entorno de uso, que comprende:preparar una composición de liberación controlada que comprende un núcleo que contiene sustancia activa y un recubrimiento polimérico asimétrico sobre él, en la que el polímero utilizado para formar dicho recubrimiento polimérico asimétrico es aquel que, cuando se ensaya mediante imbibición durante al menos 16 horas en una solución acuosa que comprende 0,5% en peso de grasa de la dieta, gana menos de aproximadamente un 15% en peso, y administrar dicha composición a dicho entorno de uso, comprendiendo dicho entorno de uso al menos aproximadamente un 0,5% en peso de grasa de la dieta.2.- Un procedimiento para la liberación controlada de una sustancia activa a un entorno de uso, que comprende:preparar una composición de liberación controlada que comprende un núcleo que contiene sustancia activa y un recubrimiento polimérico asimétrico sobre el mismo, en la que el tiempo para liberar un 50% de dicha sustancia activa desde dicha composición a dicho entorno de uso es al menos 0,5 veces, pero menos de 2,0 veces, el tiempo necesario para que dicha composición libere un 50% de dicha sustancia activa a un entorno de uso control que comprende menos de aproximadamente un 0,1 % de grasa de la dieta, y administrar dicha composición a dicho entorno de uso, comprendiendo dicho entorno de uso al menos aproximadamente un 0,5% en peso de grasa de la dieta.3.- Un procedimiento para la liberación controlada de una sustancia activa a un entorno de uso, que comprende:preparar una composición de liberación controlada que comprende un núcleo que contiene sustancia activa y un recubrimiento polimérico asimétrico sobre el mismo, en la que la cantidad de fármaco liberado de dicha composición en cualquier momento entre la 2ª y la 10a hora después de la introducción de dicha composición a dicho entorno de uso es al menos 0,5 veces, pero menos de 2,0 veces, la cantidad de dicho fármaco liberado en el mismo tiempo entre la 2a y la 10ª hora por dicha composición a un entorno de uso control que comprende menos de aproximadamente un 0,1% de grasa de la dieta, y administrar dicha composición a dicho entorno de uso, comprendiendo dicho entorno de uso al menos aproximadamente un 0,5% en peso de grasa de la dieta.
CO05056576A 2002-12-11 2005-06-10 Liberacin controlada de una sustancia activa a un entorno rico en grasa CO5570656A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43286002P 2002-12-11 2002-12-11

Publications (1)

Publication Number Publication Date
CO5570656A2 true CO5570656A2 (es) 2005-10-31

Family

ID=32508002

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05056576A CO5570656A2 (es) 2002-12-11 2005-06-10 Liberacin controlada de una sustancia activa a un entorno rico en grasa

Country Status (18)

Country Link
US (1) US20040121015A1 (es)
EP (1) EP1572163A1 (es)
JP (1) JP2006510655A (es)
KR (1) KR20050088311A (es)
CN (1) CN1726012A (es)
AR (1) AR042340A1 (es)
AU (1) AU2003283688A1 (es)
BR (1) BR0317275A (es)
CA (1) CA2508722A1 (es)
CO (1) CO5570656A2 (es)
MX (1) MXPA05005812A (es)
NO (1) NO20053068L (es)
NZ (1) NZ539915A (es)
PL (1) PL377479A1 (es)
RU (1) RU2308263C2 (es)
TW (1) TWI257302B (es)
WO (1) WO2004052343A1 (es)
ZA (1) ZA200503812B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US7906145B2 (en) 2002-04-09 2011-03-15 Flamel Technologies Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
AU2003246791A1 (en) * 2002-04-09 2003-10-20 Flamel Technologies Oral suspension of amoxicillin capsules
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US20080138428A1 (en) * 2005-01-28 2008-06-12 Pfizer Inc. Fast-Disintegrating Microporous Binders
EP1909770B1 (en) * 2005-02-22 2013-03-20 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
US8912908B2 (en) 2005-04-28 2014-12-16 Proteus Digital Health, Inc. Communication system with remote activation
US8802183B2 (en) 2005-04-28 2014-08-12 Proteus Digital Health, Inc. Communication system with enhanced partial power source and method of manufacturing same
WO2006116718A2 (en) 2005-04-28 2006-11-02 Proteus Biomedical, Inc. Pharma-informatics system
US8836513B2 (en) 2006-04-28 2014-09-16 Proteus Digital Health, Inc. Communication system incorporated in an ingestible product
US8730031B2 (en) 2005-04-28 2014-05-20 Proteus Digital Health, Inc. Communication system using an implantable device
US9198608B2 (en) 2005-04-28 2015-12-01 Proteus Digital Health, Inc. Communication system incorporated in a container
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
WO2007028035A2 (en) 2005-09-01 2007-03-08 Proteus Biomedical, Inc. Implantable zero-wire communications system
KR20140018439A (ko) 2006-05-02 2014-02-12 프로테우스 디지털 헬스, 인코포레이티드 환자 주문형 치료법
EP2087589B1 (en) 2006-10-17 2011-11-23 Proteus Biomedical, Inc. Low voltage oscillator for medical devices
KR101611240B1 (ko) 2006-10-25 2016-04-11 프로테우스 디지털 헬스, 인코포레이티드 복용 가능한 제어된 활성화 식별자
US8718193B2 (en) 2006-11-20 2014-05-06 Proteus Digital Health, Inc. Active signal processing personal health signal receivers
CN101686800A (zh) 2007-02-01 2010-03-31 普罗秋斯生物医学公司 可摄入事件标记器系统
AU2008216170B2 (en) * 2007-02-14 2012-07-26 Otsuka Pharmaceutical Co., Ltd. In-body power source having high surface area electrode
EP2063771A1 (en) 2007-03-09 2009-06-03 Proteus Biomedical, Inc. In-body device having a deployable antenna
US8932221B2 (en) 2007-03-09 2015-01-13 Proteus Digital Health, Inc. In-body device having a multi-directional transmitter
US20080299188A1 (en) * 2007-05-14 2008-12-04 Pfizer Inc. Controlled release dosage forms combining immediate release and sustainted release of low-solubility drug
US8540632B2 (en) 2007-05-24 2013-09-24 Proteus Digital Health, Inc. Low profile antenna for in body device
US8961412B2 (en) 2007-09-25 2015-02-24 Proteus Digital Health, Inc. In-body device with virtual dipole signal amplification
US8707964B2 (en) * 2007-10-31 2014-04-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090105561A1 (en) * 2007-10-17 2009-04-23 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
US8789536B2 (en) 2007-10-17 2014-07-29 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US8808276B2 (en) * 2007-10-23 2014-08-19 The Invention Science Fund I, Llc Adaptive dispensation in a digestive tract
US8808271B2 (en) * 2007-10-31 2014-08-19 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
US20090163894A1 (en) * 2007-10-31 2009-06-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Medical or veterinary digestive tract utilization systems and methods
KR100920106B1 (ko) * 2007-11-14 2009-10-01 경북대학교 산학협력단 구연산 실데나필을 경피적으로 전달하기 위한 조절 약물전달체 및 이를 포함하는 경피 패치
WO2009070773A1 (en) 2007-11-27 2009-06-04 Proteus Biomedical, Inc. Transbody communication systems employing communication channels
CN102014867A (zh) 2008-03-05 2011-04-13 普罗秋斯生物医学公司 多模式通信可摄取事件标记和系统，及使用其的方法
DK2313002T3 (en) 2008-07-08 2018-12-03 Proteus Digital Health Inc Data basis for edible event fields
CA2734251A1 (en) 2008-08-13 2010-02-18 Proteus Biomedical, Inc. Ingestible circuitry
LT2328601T (lt) 2008-08-15 2020-04-27 Ironwood Pharmaceuticals, Inc. Linaklotidą turinčios vaisto formos, skirtos vartoti per burną
KR101192690B1 (ko) * 2008-11-13 2012-10-19 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 치료 활성화 시스템, 치료 장치 및 방법
CN102271578B (zh) 2008-12-11 2013-12-04 普罗秋斯数字健康公司 使用便携式电子内脏造影系统的胃肠功能的评估及其使用方法
US9439566B2 (en) 2008-12-15 2016-09-13 Proteus Digital Health, Inc. Re-wearable wireless device
TWI424832B (zh) 2008-12-15 2014-02-01 Proteus Digital Health Inc 與身體有關的接收器及其方法
US9659423B2 (en) 2008-12-15 2017-05-23 Proteus Digital Health, Inc. Personal authentication apparatus system and method
WO2010080764A2 (en) 2009-01-06 2010-07-15 Proteus Biomedical, Inc. Pharmaceutical dosages delivery system
KR20110103446A (ko) 2009-01-06 2011-09-20 프로테우스 바이오메디컬, 인코포레이티드 섭취-관련 바이오피드백 및 개별화된 의료 치료 방법 및 시스템
WO2010111403A2 (en) 2009-03-25 2010-09-30 Proteus Biomedical, Inc. Probablistic pharmacokinetic and pharmacodynamic modeling
EP2424427B1 (en) 2009-04-28 2021-06-16 Otsuka Pharmaceutical Co., Ltd. Highly reliable ingestible event markers
WO2010132331A2 (en) 2009-05-12 2010-11-18 Proteus Biomedical, Inc. Ingestible event markers comprising an ingestible component
US8748573B2 (en) 2009-08-06 2014-06-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
EP2467707A4 (en) 2009-08-21 2014-12-17 Proteus Digital Health Inc DEVICE AND METHOD FOR MEASURING BIOLOGICAL PARAMETERS
TWI517050B (zh) 2009-11-04 2016-01-11 普羅托斯數位健康公司 供應鏈管理之系統
UA109424C2 (uk) 2009-12-02 2015-08-25 Фармацевтичний продукт, фармацевтична таблетка з електронним маркером і спосіб виготовлення фармацевтичної таблетки
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
US9014779B2 (en) 2010-02-01 2015-04-21 Proteus Digital Health, Inc. Data gathering system
US8933030B2 (en) 2010-02-17 2015-01-13 Ironwwod Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CN102905672B (zh) 2010-04-07 2016-08-17 普罗秋斯数字健康公司 微型可吞服装置
TWI557672B (zh) 2010-05-19 2016-11-11 波提亞斯數位康健公司 用於從製造商跟蹤藥物直到患者之電腦系統及電腦實施之方法、用於確認將藥物給予患者的設備及方法、患者介面裝置
DK2603232T3 (da) 2010-08-11 2019-12-09 Ironwood Pharmaceuticals Inc Stabile formuleringer af linaclotid
JP2014504902A (ja) 2010-11-22 2014-02-27 プロテウス デジタル ヘルス， インコーポレイテッド 医薬品を有する摂取可能なデバイス
JP2014514032A (ja) 2011-03-11 2014-06-19 プロテウス デジタル ヘルス， インコーポレイテッド 様々な物理的構成を備えた着用式個人身体関連装置
WO2015112603A1 (en) 2014-01-21 2015-07-30 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
US9756874B2 (en) 2011-07-11 2017-09-12 Proteus Digital Health, Inc. Masticable ingestible product and communication system therefor
CA2842952C (en) 2011-07-21 2019-01-08 Proteus Digital Health, Inc. Mobile communication device, system, and method
MX347354B (es) 2011-08-17 2017-04-24 Ironwood Pharmaceuticals Inc Tratamientos para trastornos gastrointestinales.
US9235683B2 (en) 2011-11-09 2016-01-12 Proteus Digital Health, Inc. Apparatus, system, and method for managing adherence to a regimen
KR20150038038A (ko) 2012-07-23 2015-04-08 프로테우스 디지털 헬스, 인코포레이티드 섭취 가능한 부품을 포함하는 섭취 가능한 이벤트 마커를 제조하기 위한 기술
BR112015008434A2 (pt) 2012-10-18 2017-07-04 Proteus Digital Health Inc aparelho, sistema e método para otimizar adaptativamente a dissipação de potência e a potência de radiodifusão em uma fonte de alimentação para um dispositivo de comunicação
WO2014120669A1 (en) 2013-01-29 2014-08-07 Proteus Digital Health, Inc. Highly-swellable polymeric films and compositions comprising the same
WO2014144738A1 (en) 2013-03-15 2014-09-18 Proteus Digital Health, Inc. Metal detector apparatus, system, and method
JP6498177B2 (ja) 2013-03-15 2019-04-10 プロテウス デジタル ヘルス， インコーポレイテッド 本人認証装置システムおよび方法
EP3005281A4 (en) 2013-06-04 2017-06-28 Proteus Digital Health, Inc. System, apparatus and methods for data collection and assessing outcomes
US9796576B2 (en) 2013-08-30 2017-10-24 Proteus Digital Health, Inc. Container with electronically controlled interlock
CA2965941C (en) 2013-09-20 2020-01-28 Proteus Digital Health, Inc. Methods, devices and systems for receiving and decoding a signal in the presence of noise using slices and warping
US9577864B2 (en) 2013-09-24 2017-02-21 Proteus Digital Health, Inc. Method and apparatus for use with received electromagnetic signal at a frequency not known exactly in advance
US10084880B2 (en) 2013-11-04 2018-09-25 Proteus Digital Health, Inc. Social media networking based on physiologic information
US11051543B2 (en) 2015-07-21 2021-07-06 Otsuka Pharmaceutical Co. Ltd. Alginate on adhesive bilayer laminate film
EP3487393A4 (en) 2016-07-22 2020-01-15 Proteus Digital Health, Inc. ELECTROMAGNETIC CAPTURE AND DETECTION OF INGERABLE EVENT MARKERS
TWI735689B (zh) 2016-10-26 2021-08-11 日商大塚製藥股份有限公司 製造含有可攝食性事件標記之膠囊之方法
CN111214456A (zh) * 2020-03-10 2020-06-02 浙江普利药业有限公司 伏立康唑干混悬剂及其制备方法
EP4188339A1 (en) * 2020-07-30 2023-06-07 Faes Farma, S.A. Decongestant drug delivery system
CN112198274B (zh) * 2020-11-02 2022-04-05 北京市理化分析测试中心 一种检测氨酚伪麻片中盐酸伪麻黄碱的方法
CN113514579A (zh) * 2021-06-23 2021-10-19 远大生命科学(武汉)有限公司 一种依托咪酯乳状注射液体外释放曲线的测定方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014334A (en) * 1976-02-02 1977-03-29 Alza Corporation Laminated osmotic system for dispensing beneficial agent
US4203439A (en) * 1976-11-22 1980-05-20 Alza Corporation Osmotic system with volume amplifier for increasing amount of agent delivered therefrom
US4285987A (en) * 1978-10-23 1981-08-25 Alza Corporation Process for manufacturing device with dispersion zone
US5366738A (en) * 1982-07-29 1994-11-22 Merck & Co., Inc. Controlled release drug dispersion delivery device
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US5364620A (en) * 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US4851228A (en) * 1984-06-20 1989-07-25 Merck & Co., Inc. Multiparticulate controlled porosity osmotic
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US4801461A (en) * 1987-01-28 1989-01-31 Alza Corporation Pseudoephedrine dosage form
IE60383B1 (en) * 1988-05-27 1994-07-13 Elan Corp Plc Controlled release pharmaceutical formulation
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
IE66933B1 (en) * 1990-01-15 1996-02-07 Elan Corp Plc Controlled absorption naproxen formulation for once-daily administration
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
WO1993019739A1 (en) * 1992-03-30 1993-10-14 Alza Corporation Viscous suspensions of controlled-release drug particles
US5718700A (en) * 1994-09-20 1998-02-17 Alza Corporation Exit means in dosage form
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
WO1998053802A1 (en) * 1997-05-30 1998-12-03 Laboratorios Phoenix U.S.A., Inc. Multi-layered osmotic device
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
US6136835A (en) * 1999-05-17 2000-10-24 The Procter & Gamble Company Methods of treatment for viral infections
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system

Also Published As

Publication number Publication date
US20040121015A1 (en) 2004-06-24
BR0317275A (pt) 2005-11-08
AR042340A1 (es) 2005-06-15
EP1572163A1 (en) 2005-09-14
RU2005118101A (ru) 2006-01-20
RU2308263C2 (ru) 2007-10-20
CN1726012A (zh) 2006-01-25
NZ539915A (en) 2007-09-28
ZA200503812B (en) 2006-07-26
AU2003283688A1 (en) 2004-06-30
KR20050088311A (ko) 2005-09-05
NO20053068D0 (no) 2005-06-22
MXPA05005812A (es) 2005-08-16
JP2006510655A (ja) 2006-03-30
TW200425888A (en) 2004-12-01
PL377479A1 (pl) 2006-02-06
NO20053068L (no) 2005-09-07
WO2004052343A1 (en) 2004-06-24
CA2508722A1 (en) 2004-06-24
TWI257302B (en) 2006-07-01

Similar Documents

Publication Publication Date Title
CO5570656A2 (es) Liberacin controlada de una sustancia activa a un entorno rico en grasa
CO5700698A2 (es) Composiciones y metodos para el cuidado oral y personal
PT723437E (pt) Preparacao farmaceutica por unidades multiplas contendo um inibidor da bomba de protoes
PE20001322A1 (es) Composicion multiparticula de liberacion modificada
ES2178430T3 (es) Utilizacion de composiciones farmaceuticas gelificables en parodontologia.
BR0008590A (pt) Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto
DE69902875D1 (de) Tts enthaltend ein antioxidans
AR042472A1 (es) Preparaciones de liberacion controlada que comprenden tramadol y topiramato
AR014324A1 (es) Composicion que comprende miel, utilizable en las aplicaciones alimentarias, cosmeticas, dermatologicas sobre la piel y/o sobre las mucosas, yen la desinfeccion sanitaria
ATE202698T1 (de) Topisch applizierbare pharmazeutische zusammensetzung, verfahren zu ihrer herstellung und verwendung der zusammensetzung
AR109263A2 (es) Composición que comprende moxidectina
ATE344022T1 (de) Proinsulin c-peptid enthaltende arzneizubereitung mit verzögerter wirkstofffreigabe
AR018357A1 (es) Acido petroselinico en una composicion y en un metodo para reducir o eliminar la irritacion o la picazon de la piel inducida por los alfa-hidroxiacidos
CL2004000899A1 (es) Composicion farmaceutica que contiene la sal sodica de telmisartan y un agente diuretico y procedimiento de preparacion.
AR040562A1 (es) Capsulas para la higene bucal
BRPI0606373A2 (pt) composição de xarope compreendendo dexibuprofeno como ingrediente ativo e método para a preparação da mesma
EA200702102A1 (ru) Пластинки, содержащие стероидные гормоны
DE60314722D1 (de) Zusammensetzung für die pharmazeutische oder dietätische verwendung zur bekämpfung von haarausfall
AR027748A1 (es) Pequenas esferas o globulos que contienen estavudina y permiten la liberacion controlada de la misma
Jung et al. Time of application of sodium ascorbate on bonding to bleached dentin
BR9914644A (pt) Composições tamponadas para diálise
CN101129298A (zh) 净纯牙膏
BRPI0405662A (pt) Emplastros contendo turobuterol
BRPI0417088A (pt) ativador de célula t gama delta, composição farmacêutica, uso do ativador de célula t gama delta, composição de vacina, métodos para preparar um composto, e para ativar uma célula t gama delta, célula t gama delta, e, uso da mesma
BRPI0519006A2 (pt) uso de um inibidor de fbpase, kit de uma composiÇço farmacÊutica, uso de uma preparaÇço de biguanida e um inibidor de fbpase, agente terapÊutico para diabetes melito, e, combinaÇço de agentes terapÊuticos

Legal Events

Date Code Title Description
FC Application refused